Literature DB >> 18631437

Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches.

Thomas W Gardner1, David A Antonetti.   

Abstract

This article evaluates the current knowledge of the molecular mechanisms by which diabetes ocular and systemic inflammation induce breakdown of the blood-retinal barrier resulting in macular edema. We also summarize the relationship between molecular targets and the use of therapeutic inhibitors in preclinical studies and clinical trials. Further studies are needed to understand the regulation of normal blood-retinal barrier physiology and the relationship between events in animal models of diabetic retinopathy and humans with diabetes.

Entities:  

Mesh:

Year:  2008        PMID: 18631437     DOI: 10.1007/s11892-008-0047-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  65 in total

1.  Type of diabetes mellitus associated with diabetic retinitis.

Authors:  G W DANA
Journal:  AMA Arch Ophthalmol       Date:  1953-07

2.  Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.

Authors:  Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

3.  A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

Authors:  Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale
Journal:  Ophthalmology       Date:  2007-08-15       Impact factor: 12.079

4.  Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier.

Authors:  Stephen J Giebel; Gina Menicucci; Paul G McGuire; Arup Das
Journal:  Lab Invest       Date:  2005-05       Impact factor: 5.662

5.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.

Authors:  Baruch D Kuppermann; Mark S Blumenkranz; Julia A Haller; George A Williams; David V Weinberg; Connie Chou; Scott M Whitcup
Journal:  Arch Ophthalmol       Date:  2007-03

6.  Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy.

Authors:  J Kyle Krady; Anirban Basu; Colleen M Allen; Yuping Xu; Kathryn F LaNoue; Thomas W Gardner; Steven W Levison
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

7.  Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells.

Authors:  Masaaki Seki; Takayuki Tanaka; Hiroyuki Nawa; Tomoaki Usui; Takeo Fukuchi; Kazuhito Ikeda; Haruki Abe; Nobuyuki Takei
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

8.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Ophthalmology       Date:  1998-10       Impact factor: 12.079

Review 9.  VEGF: a critical player in neurodegeneration.

Authors:  Erik Storkebaum; Peter Carmeliet
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

10.  Antihistamines reduce blood-retinal barrier permeability in type I (insulin-dependent) diabetic patients with nonproliferative retinopathy. A pilot study.

Authors:  T W Gardner; A W Eller; T R Friberg; J A D'Antonio; T M Hollis
Journal:  Retina       Date:  1995       Impact factor: 4.256

View more
  15 in total

1.  Concentration of acute phase factors in vitreous fluid in diabetic macular edema.

Authors:  Kazuhiro Kimura; Tomoko Orita; Yuka Kobayashi; Shigeo Matsuyama; Kazushi Fujimoto; Kazuhiko Yamauchi
Journal:  Jpn J Ophthalmol       Date:  2017-07-28       Impact factor: 2.447

Review 2.  Current approaches to the management of diabetic retinopathy and diabetic macular oedema.

Authors:  Francesco Boscia
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

3.  Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

Authors:  M Villarroel; M Garcia-Ramírez; L Corraliza; C Hernández; R Simó
Journal:  Diabetologia       Date:  2011-03-03       Impact factor: 10.122

4.  Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.

Authors:  Kyle Trudeau; Sumon Roy; Wen Guo; Cristina Hernández; Marta Villarroel; Rafael Simó; Sayon Roy
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-11       Impact factor: 4.799

5.  Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCζ in the Goto Kakizaki rat model.

Authors:  Samy Omri; Francine Behar-Cohen; Yvonne de Kozak; Florian Sennlaub; Lourena Mafra Verissimo; Laurent Jonet; Michèle Savoldelli; Boubaker Omri; Patricia Crisanti
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

6.  Preconditioning with endoplasmic reticulum stress mitigates retinal endothelial inflammation via activation of X-box binding protein 1.

Authors:  Jingming Li; Joshua J Wang; Sarah X Zhang
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

7.  Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.

Authors:  Neil M Bressler; Allison R Edwards; Roy W Beck; Christina J Flaxel; Adam R Glassman; Michael S Ip; Craig Kollman; Baruch D Kuppermann; Thomas W Stone
Journal:  Arch Ophthalmol       Date:  2009-12

8.  Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes.

Authors:  Li Dong; Xiao Ying Lv; Bin Jie Wang; Ye Qing Wang; Hua Mu; Zhuo Lei Feng; Ping Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-09       Impact factor: 3.117

9.  Endoplasmic reticulum stress and inflammation: mechanisms and implications in diabetic retinopathy.

Authors:  Sarah X Zhang; Emily Sanders; Joshua J Wang
Journal:  J Ocul Biol Dis Infor       Date:  2012-01-18

10.  Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial.

Authors:  Rajeev H Muni; Radha P Kohly; Eudocia Q Lee; JoAnn E Manson; Richard D Semba; Debra A Schaumberg
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.